This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Stryker Likely to Acquire Boston Scientific, Shares Down
by Zacks Equity Research
Per Reuters and The Wall Street Journal, Stryker (SYK) is likely to acquire Boston Scientific. However, there are no confirmatory statements from the company representatives.
Boston Scientific Grows on New Products Amid Recall Issues
by Zacks Equity Research
Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.
US-North Korea Summit Talks Resume: 4 MedTech Stocks to Watch
by Nabaparna Bhattacharya
Here we take a look at four leading MedTech players that are gaining from opportunities in the APAC market
Boston Scientific (BSX) Up 3.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Boston Scientific's (BSX) inorganic expansion plan bodes well for operational growth.
Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q1.
Boston Scientific (BSX) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Boston Scientific (BSX) has posted impressive results by delivering revenue growth across all segments in Q1.
Medical Product Stock Earnings Roster for Apr 25: LH & More
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?
by Zacks Equity Research
Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.
WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes
by Zacks Equity Research
The WATCHMAN platform is expected to experience a strong quarter on consistent global momentum as Boston Scientific's (BSX) multiple market development efforts continue to push for growth.
Boston Scientific to Acquire Securus Medical, Boost EP Unit
by Zacks Equity Research
Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.
Boston Scientific to Buy NxThera, Strengthens Urology Arm
by Zacks Equity Research
Even after the NxThera purchase deal culminates, it is not likely to add stimulus to Boston Scientific's (BSX) adjusted earnings per share through 2020 and prove to be accretive only later.
Can Boston Scientific's Pain be a Boon for Edwards & Others?
by Sweta Jaiswal
Boston Scientific delaying the re-introduction of Lotus Valve devices provides an edge to its competitors in the highly lucrative TAVR market.
Boston Scientific's Positive Trial Results to Boost EP Unit
by Zacks Equity Research
Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.
Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus
by Urmimala Biswas
According to Goldman Sachs, emerging markets are world's best investment in spite of several external hiccups. This comes as a breather for MedTech investors keen on exposure to emerging markets.
3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax
by Zacks Equity Research
Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.
Company News For Mar 6, 2018
by Zacks Equity Research
Companies in the news are: YY,XL,BSX,WMT
Boston Scientific Acquires EMcision, Boosts Endoscopy Unit
by Zacks Equity Research
Boston Scientific (BSX) adopts initiatives to strengthen the Endoscopy business.
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
by Zacks Equity Research
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
Millipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails
by Zacks Equity Research
Boston Scientific's (BSX) major Millipede investment might cement the company's position in the emerging mitral regurgitation field under its structural heart business.
Boston Scientific's (BSX) Q4 Earnings In Line, Sales Top
by Zacks Equity Research
Boston Scientific (BSX) has posted impressive fourth quarter results by delivering revenue growth across all segments in Q4.
Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & More
by Zacks Equity Research
As part of the amended tax policy, corporate tax rates are lowered to 21% from 35%, offering a huge relief to medical device giants.
Boston Scientific's (BSX) Millipede Deal Aids MR Business
by Zacks Equity Research
Boston Scientific (BSX) claims the Millipede IRIS annuloplasty ring to be highly customizable to a specific patient's anatomy and disease state.
Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.